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Background  and  purpose      Few  studies  have  compared  the 
long-term survival of cemented primary total hip arthroplasties 
(THAs), and several prostheses have been used without adequate 
knowledge  of  their  endurance. We  studied  long-term  outcome 
based on data in the Norwegian Arthroplasty Register.
Patients and methods   The 10 most used prosthesis brands 
in 62,305 primary Palacos or Simplex cemented THAs reported 
to the Register from 1987 through 2007 were included. Survival 
analyses with revision as endpoint (for any cause or for aseptic 
loosening) were performed using Kaplan-Meier and multiple Cox 
regression with time-dependent covariates. Revision rate ratios 
(RRs) were estimated for the follow-up intervals: 0–5, 6–10, and 
> 10 years. 
Results   5 prosthesis brands (cup/stem combinations) (Charn-
ley, Exeter, Titan, Spectron/ITH, Link IP/Lubinus SP; n = 24,728) 
were investigated with 0–20 year follow-up (inserted 1987–1997). 
After 18 years, 11% (95% CI: 10.6–12.1) were revised for any 
cause and 8.4% (7.7–9.1) for aseptic loosening. Beyond 10 years of 
follow-up, the Charnley cup had a lower revision rate due to asep-
tic loosening than Exeter (RR = 1.8) and Spectron (RR = 2.4) cups. 
For stems, beyond 10 years we did not find statistically significant 
differences comparing Charnley with Titan, ITH, and SP stems, 
but the Exeter stem had better results (RR = 0.5). 10 prosthesis 
brands (9 cups in combination with 6 stems; n = 37,577) were 
investigated  with  0–10  years  of  follow-up  (inserted  from  1998 
through 2007). The Charnley cup had a lower revision rate due 
to aseptic loosening than all cups except the IP. Beyond 5 years 
follow-up, the Reflection All-Poly cup had a 14 times higher revi-
sion rate. For stems, beyond 5 years the Spectron-EF (RR = 6.1) 
and Titan (RR = 5.5) stems had higher revision rates due to asep-
tic loosening than Charnley. The analyses also showed a marked 
improvement in Charnley results between the periods 1987–1997 
and 1998–2007. 
Interpretation   We observed clinically important differences 
between  cemented  prosthesis  brands  and  identified  inferior 
results for previously largely undocumented prostheses, including 
the commonly used prosthesis combination Reflection All-Poly/
Spectron-EF. The results were, however, satisfactory according to 
international standards.

 
A systematic review of the literature concerning outcome and 
clinical effectiveness of prostheses used for primary total hip 
arthroplasty (THA) showed that among the many cemented 
prostheses in use in Norway in 2000, only the Charnley and the 
Lubinus IP prosthesis had been reported with results beyond 
15 years of follow-up (Aamodt et al. 2004). Several of the 
prostheses in common use today have insufficient published 
documentation of clinical quality, or lack it altogether. We 
compared the survival of the 10 most used prosthesis brands 
as reported to the Norwegian Arthroplasty Register during the 
years 1987 to 2007. 
Material and methods
The Norwegian Arthroplasty Register (NAR)
The NAR was established September 15, 1987 (Havelin 1999, 
Havelin et al. 2000). Individual reports of THAs have since 
been  received  from  86  orthopedic  departments  performing 
this procedure. Information on primary operations and revi-
sions, including the identity of the patient, the date of opera-
tion, indication, type of prosthesis and cement, is reported on 
a standardized form by the orthopedic surgeon. An English 
translation of the form can be found on the register’s web-
site at http://www.haukeland.no/nrl. About 98% of all total 
hip replacements are reported to the register (Espehaug et al. 
2006). Implant failure is defined as the surgical removal or 
exchange of the whole or part of the implant. Linkage of infor-Acta Orthopaedica 2009; 80 (4): 402–412  403
mation on the primary operation and subsequent revisions is 
possible by use of the unique identification number assigned 
to each resident of Norway. 
Study sample
By  December  31,  2007,  110,882  primary THAs  had  been 
reported to the Register, 8,094 of which (7.3%) were revised 
by 2007. Only THAs with cemented acetabular and femoral 
components were eligible for inclusion in the present study 
(78%).  Furthermore,  THAs  with  unknown  information  on 
prosthesis brand or cement brand (n = 114), or on whether 
the  components  were  cemented  with  two  different  cement 
brands  (n  =  2,373),  were  excluded. An  exclusion  criterion 
was also that the prosthesis components should be cemented 
with either a Palacos type cement (Palacos plain, Palacos with 
gentamycin, Refobacin-Palacos, Palacos R+G, or Refobacin 
Bone Cement R), or a Simplex cement (Simplex plain, Sim-
plex with erythromycin and colistin, or Simplex with tobra-
mycin) (n = 74,861). Furthermore, only the 10 most common 
prosthesis brand combinations were studied, totaling 62,305 
THAs (Figure 1).
Statistics
Survival analyses used revision of either cup or stem, revision 
of cup, or revision of stem as endpoints. Separate analyses 
were performed for revisions for any cause and revisions due 
to aseptic loosening. Information on deaths or emigrations 
was retrieved from Statistics Norway, Oslo, until December 
31, 2007. The survival times of implants in patients who had 
died  or  emigrated  without  revision  of  the  prosthesis  were 
censored at the date of death or emigration. Survival times 
of unrevised prostheses were otherwise censored at the end 
of the study on December 31, 2007. Use of prosthesis brands 
changed throughout the study period (Figure 2). To ensure that 
prosthesis brands were compared within the same time period, 
separate analyses were performed for THAs done before 1998 
(with follow-up through 2007) and from 1998 through 2007. 
For the first time period, we studied 5 prosthesis combina-
tions that had been used in more than 250 hips (5 different 
cups and 5 different stems). For the second time period, all 10 
prosthesis combinations were studied (9 different cups and 6 
different stems).
Overall  revision  percentages  were  estimated  using  the 
Kaplan-Meier method. Median follow-up was calculated for 
each prosthesis brand following the reversed Kaplan-Meier 
method (Schemper and Smith 1996). Cox regression analyses 
with prosthesis brand as stratification factor were used to con-
struct prosthesis-specific survival curves adjusted for sex, age 
(< 60, 60–69, 70–79, > 79), diagnosis (osteoarthritis, other), 
use of systemic antibiotic prophylaxis (no, yes) and cement 
Figure 1. Description of the study selection procedure. 
a   Palacos  cement  types:    Palacos  plain,  Palacos  with 
gentamycin,  Refobacin  –  Palacos,  Palacos  R  +  G,  and 
Refobacin Bone Cement R, and 
  Simplex cement: Simplex plain, Simplex with erythromy-
cin/ colistin, and Simplex with tobramycin. Same cement 
brand in acetabulum and femur.
 
   
   
a Palacos cement types:  Palacos plain, 
Palacos with gentamycin, Refobacin - 
Palacos, Palacos R + G, and Refobacin 
Bone Cement R, and 
  Simplex cement: Simplex plain, Simplex 
with erythromycin/ colistin, and Simplex 
with tobramycin. Same cement brand in 
acetabulum and femur.
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Figure 2. Time trends in the use of the 10 most common cemented prosthesis 
brands in Norway 1989–2007.404  Acta Orthopaedica 2009; 80 (4): 402–412
brand (8 brands). In the Cox models, the covariate age was 
represented with indicator variables since the assumption of a 
log-linear relationship between age and the revision rate was 
not justified. The survival curves for the adjusted percentage 
of unrevised implants were constructed for times when more 
than 50 implants remained at risk of revision. Adjusted revi-
sion rate ratios (incidence rate ratios) (RRs) for the different 
prosthesis brands are presented with 95% confidence intervals 
and p-values relative to the Charnley prosthesis. Charnley was 
chosen as a reference because it was used in large numbers 
throughout the study period. To investigate the proportional 
hazards assumption of the Cox model (meaning that the rela-
tive difference between revision rates should be constant over 
time since the primary operation), we used tests and visual 
inspection of plotted scaled Schoenfeld residuals (Grambsch 
et al. 1995). These analyses showed that some of the prosthe-
sis brands did not satisfy this assumption. Adjusted revision 
rate ratios were therefore established also within time intervals 
(0–5 years, 6–10 years, and > 10 years after the primary opera-
tion) using an extended Cox model including time-dependent 
covariates.  The  time-dependent  covariates  were  based  on 
heavy side functions with cut-points at 5 and 10 years. 
To investigate whether the adjusted log RRs changed with 
year of operation, we fitted an extended Cox model based on 
generalized additive models for survival data with penalized 
splines (Hastie and Tibshirani 1990). This smoothing method 
makes no assumptions about the shape of the association, and 
therefore  permits  estimation  of  non-linearities.  The  graphs 
(Figure 6) were calibrated so that the log RR was set to zero 
at the mean year of operation. A horizontal line was added to 
show this reference level. The graphs are presented with 95% 
confidence intervals, together with the results of a linear trend 
test and a test of non-linearity in the effect of year of operation 
on survival. To ensure at least 5 years of follow-up, only THAs 
operated before 2003 were included in this analysis.
All p-values less than 0.05 were considered statistically sig-
nificant. The statistical software programs S-Plus 7 (Insightful 
Corp., Seattle, WA) and SPSS version 15.0 (SPSS Inc., Chi-
cago, IL) were used.
Results
During the period 1987–2007, 4 of the 10 prosthesis brand 
combinations (cup/stem) constituted 85% of the operations 
(Table 1). Only 3 brands—Charnley, Exeter, and Titan—were 
used consistently throughout the period (Figure 2). Except for 
the monoblock Charnley prosthesis with a 22.225-mm head 
(47%),  most  stems  had  28-mm  modular  heads  (36%). All 
cups were UHMPWE (Table 1). Most of the caput prostheses 
were of stainless steel (63%), CoCr (26%), or alumina (10%). 
Overall, 28% of the operations involved males, the median 
patient age at operation was 73 years with 7.5% younger than 
60 years, and 75% of patients were operated due to primary 
osteoarthritis. The cement Palacos with gentamicin was used 
in 64% of the operations (Table 2). Time trends were observed 
Table 1. Prosthesis characteristics for cemented prosthesis combinations in 62,305 total hip replacements, Norway 1987–2007 
        Caput
                   
          Material f %         Modular    
Prosthesis      Cup  Stem    Diameter  Modular  brand
(cup/stem)  n  Manufacturer  material d  material  surface e  Steel   CoCr   Alum.  Other g   (%) h   %   (%) i 
Charnley   29,577   DePuy   U    Steel   MV   100   0   0   0   22 (100)  0   –
Exeter   10,003   Stryker, Osteonics,   U    Steel   P    59   0.2   40   0.0   28 (51)   97  Exeter (100)
    Howmedica                   
Reflection a/   7,285  Smith & Nephew   U    CoCr   MR     0   89   6.3   4.4   28 (93)   100   Universal (95)
Spectron-EF                        
Titan   6,250   Landos, DePuy   U    Ti   S    51   46   2.5   0   28 (70)   100   Landos (57)
Spectron/ITH b   2,355   Smith &  Nephew  U    Ti   MS   0   97   3.1  0.1   32 (100)   100   Universal (96)
IP/SP (I, II) c   2,014  Waldemar Link    U    CoCr   M    0   99   1.1   0   28 (94)   90   SP II (100)
Contemporary/  1,571   Stryker, Howmedica  U    Steel   P    0.3   0.2  100   0   28 (100)   100   Exeter (99)
Exeter                       
Kronos/Titan   1,303   Landos, DePuy  U    Ti   S    5.7   86   8.3   0   28 (100)   100   Fjord (85)
Elite/Titan   1,032   DePuy/Landos, DePuy  U    Ti   S    1.1   98   0.9   0   28 (98)   100   Fjord (97)
Reflectiona/ITHb   915   Smith & Nephew  U    Ti   MS   0   95   0   5.3   28 (92)   100   Universal (92)
a  Full brand name: Reflection Cemented All-Poly.
b The ITH femoral prosthesis is not in current use.
c  Full brand name: Link IP/Lubinus SP I (n = 205) and Link IP/Lubinus SP II (n = 1,809).
d U – ultrahigh molecular weight polyethylene. 8 cups with unknown material.
e  Surface: M – matt; MV – matt vaquasheen; MR – matt, roughened proximally; P – polished; S – smooth; MS – matt, sandblasted
f  Unknown material in 981 modular heads. 
g Zirconium (n = 334) and Oxinium (n = 37).
h The most commonly used caput diameter (mm). Information was not available in 184 cases.
i  The most common caput prosthesis brand among modular stems. Information was not available in 61 cases.Acta Orthopaedica 2009; 80 (4): 402–412  405
in the use of cement brands, where all 3 cement brands used 
in 2007 had been recently introduced (Figure 3). 2 of the pros-
theses, Kronos/Titan and Elite/Titan, had been used in few 
hospitals with at least 90% of the operations performed at the 
same hospital.
Cemented THAs 1987–1997 (with follow-up until 2007)
5 of the 10 prosthesis cup/stem combinations had been used in 
more than 250 operations during the years 1987–1997 (Table 
3), totaling 24,728 THAs. After 18 years, 11.3% (95% CI: 
10.6–12.1) of these were revised for any cause, 8.4% (7.7–9.1) 
due to aseptic loosening, 5.3% (4.7–5.9) due to aseptic loosen-
ing of the cup, and 5.9% (5.3–6.4) due to aseptic loosening of 
the stem. We observed that all prosthesis combinations inserted 
during the period 1987–1997 had similar or better early sur-
vival (all causes of revision) than the Charnley (Table 4). How-
ever, beyond 10 years of follow-up, revision rates were higher 
for Exeter (RR = 1.4; 95% CI: 1.1–1.8) and Spectron/ITH (RR 
= 1.7; 1.3–2.2) (Table 4), indicated by a steeper decline of 
the survival curve beyond 10 years for these prostheses com-
pared to that of the Charnley (Figure 4a). There were similar 
findings with revision due to aseptic loosening as endpoint, 
although beyond 10 years only Spectron/ITH (RR = 1.9; 1.4–
2.5) had a statistically significantly higher revision rate com-
pared to the Charnley (Figure 4b, Table 4). With revision due 
to aseptic loosening of the cup, we observed no statistically 
significant differences between the 5 cups with follow-up of 
up to 10 years, but beyond 10 years revision rates were higher 
for the Exeter (RR = 1.8; 1.3–2.6) and the Spectron (RR = 
2.4; 1.7–3.4) cups compared to the Charnley (Figure 4c, Table 
4). The same results were obtained when 2,059 metal-backed 
Exeter cups were excluded from the analysis. Although Titan, 
ITH, and SP stems had lower revision rates due to aseptic 
loosening than Charnley with short follow-up, we observed no 
statistically significant differences to the Charnley beyond 10 
years. In contrast to the results for cups, the Exeter stem per-
formed better than the Charnley throughout follow-up (RR = 
0.4; 0.3–0.5) (Figure 4d, Table 4).
Cemented THAs 1998–2007
All 10 prosthesis brand combinations had been used in more 
than 250 operations during this period (Table 3), totaling 37,577 
THAs. The relative differences in prosthesis survival as com-
Table 2. Patient and procedure characteristics for cemented prosthesis combinations in 62,305 total hip replacements, Norway 1987–2007 
   No. of hospitals with        Cement brand (%)
   n   n > 10   n > 250   Men  < 60 years  Median  OA  Palacos  Palacos  Simplex   Simplex   Palacos
Prosthesis (cup/stem)        %   %   age   % c     G d     E/C or T d   types e
Charnley   29,577   49   35   28   8.2   73   73   9.8   78   3.1   0.1   8.8
Exeter   10,003   17   10   29   8.6   72   79   0.7   26   33   33   7.7
Reflection a/Spectron-EF   7,285   16   10   28   7.9   74   80   0.4   65  4.8   4.4   25
Titan   6,250   19  6   27   2.2   75   75  9.2   78   1.8   0.1   11
Spectron/ITH   2,355   4   2   30   6.9   72   75   7.0   38   52   2.8   0.2
IP/SP (I, II) b   2,014   12   2   30   6.3   74   76   4.9   47   6.2   0.0   42
Contemporary/Exeter   1,571   10   1   33   12   72   83   0   19  3.9   9.8   67
Kronos/Titan   1,303   4   1   25   9.4   75   66   0.1   78   0  0   22
Elite/Titan   1,032   3   1   30   0.8   75   82   0   70   0   0   31
Reflectiona/ITH   915   6   1   30   5.0   74   75   0   92   6.7   0.7   0.9
Overall   62,305   74   58   28   7.5   73   75   6.2   64   9.8   6.3   14
a Full brand name: Reflection Cemented All-Poly.
b Full brand name: Link IP/Lubinus SP I (n = 205) and Link IP/Lubinus SP II (n = 1,809).
c OA: osteoarthritis of the hip; information was not available on primary diagnosis in 400 cases.
d G: gentamicin; E/C: erythromycin/colistin; T: tobramycin
e Palacos types: Refobacin-Palacos (n = 1,652), Palacos R+G (n = 4,278), and Refobacin Bone Cement R (n = 2,458).
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Figure 3. Time trends in the use of cement brands in Norway 1989–
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pared to Charnley during this period (1998–2007) increased 
relative to our findings for the first time period (1987–1997). 
This was mainly due to a marked improvement in results for 
the Charnley from an estimated 8-year revision percentage of 
5.3% (4.9–5.7) in the first period to 2.7% (2.3–3.1) in the last 
period with any revision as endpoint, and from 3.6% (3.3–4.0) 
to 0.7% (0.5–0.9) with revision due to aseptic loosening as 
endpoint. Except for Spectron/ITH and IP/SP, all prostheses 
Table 3. Median follow-up a and number at risk, for total hip arthroplasties inserted 1987–1997 (follow-up 
until 2007) and 1998–2007 
    1987–1997      1998–2007
    Number at risk by    Number at risk by 
    Median  years after operation  Median  years after operation
Prosthesis (cup/stem)  FU (years)  0   10   18  FU (years)   0   8
Charnley    11    14,842   8,633   805    5.1    14,735   2,280
Exeter    12    3,934   2,562   326    4.1    6,069   653
Reflection b/Spectron-EF    10    66   48   0    3.6    7,219   242
Titan    11    3,205   1,758   92    4.5    3,045   461
Spectron/ITH    12    2,019   1,239   96    7.6    336   130
IP/SP (I, II) c    11    413   240   27    2.2    1,601   160
Contemporary/Exeter    0    0   0   0    1.3    1,571   0
Kronos/Titan   0    0   0   0    4.4    1,303   187
Elite/Titan    10    11   4   0    3.8    1,021   0
Reflectionb/ITH    10    238   138   0    6.4    677   185
Overall    11    24,728   14,622   1,346    4.2    37,577   4,298
a Median follow-up (FU) calculated using the reversed Kaplan-Meier method.
b Full brand name: Reflection Cemented All-Poly. 
c Full brand name: Link IP/Lubinus SP I (n = 205) and Link IP/Lubinus SP II (n = 1,809).
Table 4. Cox regression results a for cemented prosthesis brand combinations inserted 1987–1997 with follow-up until 2007 (n = 24,728) 
  0–20-year follow-up    Revision %  6–10-year follow-up    11–20-year follow-up
 
Cause of revision   No.   RR   95% CI   p-value    8-year  18-year   95% CI    No.   RR   p-value  No.   RR   p-value
  Prosthesis  revised              revised      revised
All causes 
  Charnley   1,141   1          5.3   12   11–13    406   1       242   1 
  Exeter   330   0.9   0.8–1.1   0.3    3.9   12   10–15    102   0.8   0.1    124   1.4   0.02
  Titan   146   0.7   0.6–0.8   < 0.001    3.0   9.7   7.2–12    51   0.7   0.01    39   1.0   1.0
  Spectron/ITH   135   0.8   0.7–1.0   0.02    2.2   11   9.3–14    49   0.8   0.2    67   1.7   < 0.001  
  IP/SP (I, II) b   8   0.3   0.1–0.6   < 0.001    1.6   c   c    1   0.1   0.02    2   0.3   0.1
Aseptic loosening 
  Charnley   851   1          3.6   8.6   7.8–9.5    340   1       203   1 
  Exeter   219   0.8   0.6–1.0   0.03    2.1   8.8   6.9–11  74  0.7   0.01    96   1.3   0.1
  Titan   100   0.7  0.5–0.8   < 0.001    1.8   6.8   5.1–8.9  43   0.7   0.02    32   1.0   1.0
  Spectron/ITH   119   0.9   0.7–1.1   0.4    1.7   9.7   7.8–12    46   0.9   0.5    62   1.9   < 0.001
  IP/SP (I, II) b   3   0.1   0.0–0.6   0.001    0.3   c   c    1   0.1   0.03    2   0.4   0.2
Aseptic loosening of cup 
  Charnley   417   1      1.4   4.5   3.9–5.2    152   1       136   1 
  Exeter   188   1.4   1.1–1.9   0.01    1.7   7.6   5.7–9.7    59   1.3   0.2    88   1.8   < 0.001
  Titan   76   1.1   0.8–1.4   0.5    1.3   5.4   3.8–7.0    33   1.2   0.4    27   1.3   0.2
  Spectron   90   1.4   1.1–1.8   0.003   0.9   7.5   5.7–9.2    33   1.5   0.05    53   2.4   < 0.001
  IP b   2  0.2   0.1–0.8   0.03    0.3   c   c    1   0.3   0.2    1   0.3   0.3
Aseptic loosening of stem                
  Charnley   789   1          3.5   7.8   7.0–8.6    321   1     1  178   1 
  Exeter   106   0.4   0.3–0.5   < 0.001    1.1   3.9   2.7–5.1    35   0.3   < 0.001    40   0.5   0.002
  Titan   63   0.5   0.4–0.6   < 0.001    1.2   4.0   2.9–5.2    26   0.5   < 0.001    21   0.7   0.2
  ITH   59   0.5   0.4–0.6   < 0.001    1.3   4.1  3.0–5.3    25   0.5   < 0.001    24   0.8  0.3
  SP (I, II) b   3   0.1   0.0–0.5   0.001    0.3   c   c    1   0.1   0.03    2   0.4   0.2
a Revision rate ratios (RRs) and revision percentages with adjustment for sex, age, diagnosis, and cement brand. 
b Full brand name: Link IP/Lubinus SP I (n = 205) and Link IP/Lubinus SP II (n = 1,809).
c Less than 50 prostheses at risk.Acta Orthopaedica 2009; 80 (4): 402–412  407
survival than the Charnley. The highest revision rates as com-
pared with the Charnley were observed for the Reflection All-
Poly/Spectron-EF and Elite/Titan combinations. 
Strengths and limitations
The study was based on information given to NAR by ortho-
pedic surgeons since 1987. Ideally, the quality of prostheses 
should  be  evaluated  in  high-powered  randomized  clinical 
trials, but for practical and economic reasons (Black 1996) 
such trials are seldom performed for long-term comparison 
of hip implants. In register based studies, the findings may 
also be considered representative for a wider range of patients 
and surgeons. Registration completeness of hip replacements 
had statistically significantly higher revision rates due to asep-
tic loosening than the Charnley (Figure 5b, Table 5). 9 cups 
were investigated. Compared with the Charnley and with revi-
sion due to aseptic loosening of the cup as endpoint, beyond 
5 years we found higher revision rates for all cups except for 
the IP (Figure 5c, Table 6). Compared to the Charnley, the 
highest revision rates due to aseptic loosening were found for 
Reflection All-Poly (RR = 14; 7.2–28) and Elite (RR = 23; 
7.8–67) cups. 6 stems were investigated and 2 of these, the 
Spectron-EF (RR = 6.1; 3.1 - 12) and Titan (RR = 5.5; 2.9–11) 
had inferior results to Charnley (Figure 5d, Table 6). 
In this study, the Exeter was the most common prosthesis in 
2007. With revision due to aseptic loosening of the cup as end-
point and the Exeter as reference (results not 
shown in tables), in the 6–10-year time inter-
val we observed better results for Charnley 
(RR = 0.2; 0.1–0.4), and inferior results for 
Reflection All-Poly (RR = 2.3; 1.2–4.3) and 
Elite (RR = 3.6; 1.3–10) cups. With revision 
due to aseptic loosening of the stem as end-
point and the same time interval, we observed 
inferior results for Spectron-EF (RR = 3.1; 
1.2–8.0) and Titan (RR = 2.8; 1.1–7.1) stems 
compared to the Exeter. The other brands of 
stem did not perform statistically significantly 
different from the Exeter. 
Although it was used in over 1,500 opera-
tions and being the third most used prosthesis 
in 2007, the Contemporary/Exeter combina-
tion could not be evaluated due to the short 
follow-up time (median 1.3 years).
Time trends
Extended Cox regression analyses showed a 
reduction in the risk of revision due to asep-
tic loosening since about 1995 (p for linearity 
= 0.003) (Figure 6). However, excluding the 
Charnley prosthesis, we observed an increase 
over time in revision risk due to aseptic loos-
ening (p for linearity < 0.001) (Figure 6). 
Discussion
Overall  survival  for  THAs  inserted  early 
(1987–1997)  and  late  (1998–2007)  showed 
short-term and long-term results that were sat-
isfactory according to international standards 
(Aamodt et al. 2004). However, we observed 
clinically important differences between com-
monly used cemented prosthesis brands. The 
results for the Charnley prosthesis improved 
markedly  over  time,  and  in  the  last  time 
period none of the other prostheses had better 
Survival (%), 
revision: any cause
Survival (%), 
revision: aseptic loosening
Survival (%), 
revision: aseptic loosening cup
Survival (%), 
revision: aseptic loosening stem
Years Years
Years Years
Figure 4. Prosthesis survival with revision of either cup or stem for any cause (a), revision 
of either cup or stem due to aseptic loosening (b), revision of cup due to aseptic loosening 
(c), or revision of stem due to aseptic loosening, (d) as endpoint, for 5 cemented prosthe-
ses operated 1987–1997 with follow-up through 2007. 
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in the NAR is high (98%), both for primary operations and for 
revisions (Espehaug et al. 2006). Information on registration 
of selected variables has been validated based on data from 
one high-volume hospital, and few errors were observed in the 
registration of date of operation (1.1%) and in laterality (0.2%) 
(Arthursson et al. 2005). However, both the Danish and the 
Swedish hip arthroplasty registers have 
expressed caution regarding the validity 
of the registration of primary diagnoses 
(Pedersen  et  al.  2004,  Kärrholm  et  al. 
2007). Comparison of prosthesis brand 
survivorship in observational studies may 
give results confounded by patient and 
procedure  characteristics. We  observed 
distributional differences both in patient 
characteristics and in the use of cement 
brands. In our study, we limited the study 
population to patients with implants fix-
ated  with  brands  of  cement  that  had 
reported  satisfactory  results  (Espehaug 
et al. 2002). However, although shown to 
have comparable mechanical properties, 
handling curves and viscoelastic proper-
ties may not be identical for more recent 
cement preparations as compared to their 
predecessors (Dall et al. 2007). Further-
more, prosthesis survival for these cement 
preparations is largely unknown. We thus 
treated cement brand as a possible con-
founder in the statistical analyses along 
with sex, age, and diagnosis. Differences 
in survival may also be confounded by 
other factors not reported to the regis-
ter,  possibly  surgeon-related  or  associ-
ated with time of the study. With this in 
mind, analyses were performed based on 
data from 2 time periods. One may also 
criticize the use of revision as endpoint, 
ignoring the high proportion of clinically 
and radiologically loose implants (Hul-
leberg  et  al.  2008). Although  the  total 
percentage  of  failure  would  be  higher, 
however, it is unlikely that the relative 
differences  between  prosthesis  brands 
would be affected. 
Prosthesis brands studied over 
2 time periods: 1987–1997 and 
1998–2007
Before 1998, the Charnley cup did well 
compared to others while the Charnley 
stem had inferior results—at least with 
short-term  follow-up.  Most  Charnley 
cups  were  OGEE-flanged,  which  has 
Figure 5. Prosthesis survival with revision of either cup or stem for any cause (a), revision of 
either cup or stem due to aseptic loosening (b), revision of cup due to aseptic loosening (c), 
or revision of stem due to aseptic loosening, (d) as endpoint, for 10 cemented prostheses 
operated 1998–2007.
Survival (%), 
revision: any cause
Survival (%), 
revision: aseptic loosening
Survival (%), 
revision: aseptic loosening cup
Survival (%), 
revision: aseptic loosening stem
Years Years
Years Years
been  shown  to  give  good  cementation  (Hodgkinson  et  al. 
1993). The 22.225-mm head has also been shown to give 
lower wear rates than 28- and 32-mm heads, resulting in less 
aseptic loosening (Wroblewski et al. 2004). From about 1995, 
the results for both the Charnley cup and the Charnley stem 
improved markedly. The reason for this cannot be explained 
c) d)
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Table 6. Cox regression results a with revision of either cup or stem as endpoint, for cemented prosthesis brand combinations inserted 
1998–2007 (n = 37,577)
   0–10-year follow-up   Revision %   6–10-year follow-up
Cause of revision                
  Prosthesis   No. primary   No. revised   RR   95% CI  p-value    8-year   95% CI    No. revised   RR   p-value
Aseptic loosening of cup         
   Charnley   14,735   52   1          0.4    0.3–0.6    11   1 
  Exeter   6,069   60   3.2   2.0–5.3   < 0.001   1.3    0.7–2.0    26   6.2   < 0.001
   Reflection b   7,896   79   4.4   3.1–6.3   < 0.001    2.4    1.5–3.2    37   14   < 0.001
   Titan   3,045   20   2.4   1.4–4.0   0.001    1.1    0.5–1.6   6   3.3   0.02
   Spectron   336   6   3.3   1.0–11   0.05    1.0   -0.3–2.3    4   6.0   0.01
   IP c   1,601   4   0.9   0.3–2.8   0.8    0.4   -0.1–0.8    1   0.0   0.6
   Contemporary   1,571   1   1.3   0.2–9.5   0.8    d    d    0   d   d
   Kronos   1,303   7   1.9   0.8–4.1  0.1   0.7    0.0–1.3    3   3.8   0.04
   Elite   1,021   10   5.6   2.8–11   < 0.001    d    d    5   23   < 0.001
Aseptic loosening of stem            
   Charnley   14,735   58   1          0.5    0.3–0.7    17   1 
   Exeter   7,640   26   1.3  0.8–2.5   0.3    0.9    0.3–1.6    9   2.0   0.2
   Spectron-EF   7,219   49   2.6   1.8–3.9   < 0.001    1.8    0.9–2.6    18   6.1   < 0.001
   Titan   5,369   65   4.2   2.9–6.1   < 0.001    2.1    1.3–2.8    23   5.5   < 0.001
   ITH   1,013   11   0.9   0.4–2.0   0.8    0.4    0.1–0.7    6   1.4   0.6
   SP (I, II) c   1,601   2  0.5   0.1–2.1  0.4   0.2  -0.1–0.4    0   0.0   0.5
a Revision rate ratios (RRs) and revision percentages with adjustment for sex, age, diagnosis, and cement brand. 
b Full brand name: Reflection Cemented All-Poly. 
c Full brand name: Link IP/Lubinus SP I (n = 205) and Link IP/Lubinus SP II (n = 1809).
d Less than 50 prostheses at risk.
Table 5. Cox regression results a with revision of either cup or stem as endpoint, for cemented prosthesis brand combinations inserted 
1998–2007 (n = 37,577) 
     0–10-year follow-up    Revision %  6–10-year follow-up
Cause of revision                
  Prosthesis   No. revised   RR   95% CI   p-value    8-year   95% CI    No. revised   RR   p-value
All causes           
  Charnley   324   1         2.7    2.3–3.1    45   1 
   Exeter   170   1.6   1.3–2.1   < 0.001    5.2    4.0–6.4    40   3.2   < 0.001
   Reflection b/Spectron-EF   190   1.6   1.3–1.9   < 0.001    6.0    4.5–7.4    38   5.2   < 0.001
  Titan   104   1.8   1.4–2.2   < 0.001    4.9    3.9–6.0    15   2.0   0.03
  Spectron/ITH   11   1.1   0.5–2.3   0.8    2.6    0.6–4.6    5   2.0   0.2
   IP/SP (I, II) c   38   1.4   1.0–2.0   0.08    3.0    1.9–4.1    3   0.3   0.3
   Contemporary/Exeter   16   1.1   0.6–1.8   0.8    d    d    0   d   d
   Kronos/Titan   48   1.9   1.4–2.6   < 0.001    5.4    3.6–7.2    11   3.4   < 0.001
   Elite/Titan   35   2.1   1.5–3.0   < 0.001    d    d    11   9.8   < 0.001
  Reflectionb/ITH   23   1.2   0.8–1.9   0.4    3.3    1.8–4.8    6   1.8   0.2
Aseptic loosening            
  Charnley   77   1          0.7    0.5–0.9    21   1 
   Exeter   70   2.4   1.6–3.8   < 0.001    1.6    0.9–2.3    28   3.5   < 0.001
   Reflection b/Spectron-EF   87   3.8   2.7–5.2   < 0.001    3.4    2.1–4.7    35   10   < 0.001
   Titan   41   3.3   2.3–4.9  < 0.001   2.3    1.5–3.1    11   3.3   0.002
  Spectron/ITH   8   1.4   0.6–3.7   0.5    0.7    0.0–1.5    5   2.1   0.2
   IP/SP (I, II) c   5   0.8   0.3–2.1   0.6    0.4   -0.0–0.9    1   0.0   0.5
   Contemporary/Exeter   1   0.7   0.1–4.8   0.7    d    d    0   d   d
   Kronos/Titan   18   3.2   1.9–5.4   < 0.001    3.1    1.2–5.0    7   4.8   < 0.001
   Elite/Titan   17   6.2   3.6–11   < 0.001    d    d    9   21   < 0.001
   Reflectionb/ITH   11   2.0   1.0–3.8   0.05    1.3    0.3–2.2    6   3.8   0.005
a Revision rate ratios (RRs) and revision percentages with adjustment for sex, age, diagnosis, and cement brand. 
b Full brand name: Reflection Cemented All-Poly. 
c Full brand name: Link IP/Lubinus SP I (n = 205) and Link IP/Lubinus SP II (n = 1809).
d Less than 50 prostheses at risk.410  Acta Orthopaedica 2009; 80 (4): 402–412
based on the data in the register, but it is known that from the 
mid-1990s onward, most surgeons using the prosthesis have 
been  taught  improved  surgical  technique.  Another  reason 
may be that the decrease in the use of Charnley prostheses 
might indicate that there may have been a selected group of 
dedicated surgeons that did not change to other brands of 
prosthesis.
Overall, the revision rates due to aseptic loosening were 
similar for Charnley and Exeter, but the long-term risk of asep-
tic loosening was higher for Exeter cups and lower for Exeter 
stems. This could be influenced by head size (51% for 28 mm 
and 39% for 30 mm, for the Exeter), sterilization procedures, 
the quality of polyethylene, design, surgical techniques, or a 
combination of these. This finding is corroborated by other 
studies showing excellent 12-year results for the Exeter stem, 
but not so for the Exeter cup (Williams et al. 2002, Lewthwaite 
et al. 2008). Inferior results have been reported with metal-
backed Exeter cups in combination with the modular Exeter 
Universal stem (Hook et al. 2006). In our study, over 2,000 of 
the Exeter cups where metal-backed, but this had only mar-
ginal influence on the results. 
Concern has been raised about the use of titanium stems 
in cemented prostheses (Jacobsson et al. 1995, Willert et al. 
1996, Thomas et al. 2004). Our study showed that while the 
Titan stem did better than the Charnley in the first period, 
the opposite was true in the second period. This was not the 
case for the ITH stem, which is also made of titanium. While 
potentially important risk factors such as cementing technique 
and cement-mixing systems were not reported to the Nor-
wegian Arthroplasty  Register,  the  use  of  so-called  modern 
cementing  techniques  was  common  in  Norway  throughout 
the last study period. The NAR has been informed that some 
of the titanium stems were inserted according to ‘the French 
paradox’ (Langlais et al. 2003), a method that was commonly 
used during the early years at some of the hospitals using tita-
nium stems. Although criticized (Huiskes 1980, Anthony et al. 
1990), the method has also been shown to give results similar 
to those using prostheses with a complete and thicker (≥ 2-
mm) cement mantle (Skinner et al. 2003). Two French groups 
have also reported a stem revision rate of less than 1% due to 
aseptic loosening for cemented titanium stems designed to fill 
the medullary canal with the largest possible size (Nizard et al. 
1992, LeMouel 1998). 
The Spectron cup initially had better results than the Charn-
ley cup, but this changed with longer follow-up—probably 
due to the 32-mm heads used with the Spectron cup (Wro-
blewski et al. 2004). Satisfactory short-term results have also 
been  reported  previously,  based  on  data  in  the  Norwegian 
Arthroplasty Register (Espehaug et al. 1995). Other studies 
have reported 4.1% revision after 11 years for the Spectron 
cup (Garellick et al. 2000). 
We  observed  low  revision  rates  for  the  IP/SP  prosthesis 
(90% SP II stems). This is in accordance with those reported 
for the SP II prosthesis from other register-based studies with 
a 10-year revision rate due to aseptic loosening of 4.3% (Mal-
chau et al. 2002). However, in our study only 240 IP/SP com-
binations had been followed for more than 10 years.
Figure 6. A graphical representation of the relationship between year of operation (1987–2002) and the log revision rate ratio with aseptic loos-
ening as endpoint for all prostheses (a), Charnley prostheses (b), and all prostheses excluding Charnley (c). The graphs show 95% confidence 
intervals, together with results of a linear trend test and a test of non-linearity in the effect of year of operation. The graph is calibrated with the log 
revision rate ratio set to zero at the mean year of operation. The horizontal line shows the reference level.
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Prosthesis brands studied for one time period: 
1998–2007
The Reflection All-Poly cup and the cobalt-chrome Spectron-
EF  stem  was  the  most  common  prosthesis  combination  in 
2007 (with no restrictions regarding cement brand and includ-
ing  cups  with  highly  crosslinked  polyethylene).  Compared 
with either the Charnley or the Exeter prosthesis, both the cup 
and the stem had higher revision rates. The 2007 annual report 
from the Swedish Hip Arthroplasty Register showed a revi-
sion rate (for any cause) at 10 years for this prosthesis combi-
nation of 8% (Kärrholm et al. 2008), which is similar to our 
findings of 6% at 8 years. An RSA study showed that cups 
with  EtO-sterilized  polyethylene  (including  the  Reflection 
All-Poly cup) had almost twice the proximal and 3D femoral 
head penetration rates after 2 years as those with gamma-ster-
ilized polyethylene (Digas 2005). The modular Spectron-EF 
stem was introduced in 1988, and in 1989 the roughness of the 
proximal part of the stem was increased. 2 publications have 
reported massive femoral osteolysis and metallosis for this 
stem and suggest that the addition of a rough surface to the 
Spectron stem has been detrimental to the long-term success 
of the prosthesis (Gonzalez Della Valle et al. 2006, Grose et al. 
2006). Several studies have reported acceptable results (Garel-
lick et al. 2000, Issack et al. 2003) for the monoblock Spectron 
stem that preceded the Spectron-EF stem, with a 16-year revi-
sion rate for aseptic loosening of 6.1% (Issack et al. 2003). It 
has been argued that a small stem in combination with a high 
offset will increase the risk of revision (Kärrholm et al. 2006). 
In our study, the number of Spectron-EF stems with this par-
ticular combination was small (n = 202), and when these were 
excluded we obtained similar results. The prosthesis combina-
tion Reflection All-Poly/ITH also had a higher revision rate 
due to aseptic loosening than Charnley, but this rate was not 
significantly different from that of the Exeter. We have not 
found any published reports for this prosthesis combination. 
We could not find any published reports for the Kronos/Titan 
combination either, or for the Kronos cup. Our results should 
be interpreted with caution, as the Kronos/Titan combination 
was used mainly in one hospital.
Inferior results were noted for the Elite cup in combination 
with the Titan stem, as compared to either Charnley or Exeter. 
The Elite cup has the same manufacturer as the Charnley, and 
is the same except that it can be used with larger heads (98% 
with 28-mm heads). The finding for the Elite cup is in accor-
dance with the concern raised by Walton et al. (2005) after 
observing a high degree of radiological loosening both for the 
acetabular and femoral Elite Plus components at a mean of 
6 years postoperatively (Walton et al. 2005). Based on regis-
ter data, inferior 5-year results have also been shown for the 
Elite/Charnley combination (Espehaug et al. 1995). However, 
it should be noted that the Elite/Titan combination was used 
mainly in one hospital.
With a median follow-up time of 1.3 years, the Contem-
porary/Exeter combination had the shortest follow-up. Even 
though the combination was one of the most commonly used 
prostheses in 2007, it could not be evaluated, and as far as we 
know no results have been reported from other studies. 
Conclusion
We  observed  clinically  important  differences  between 
cemented prosthesis brands and identified inferior results for 
previously  largely  undocumented  prostheses,  including  the 
commonly used prosthesis combination Reflection All-Poly/
Spectron-EF. The study has further demonstrated the impor-
tance of long-term follow-up, as several of the prostheses with 
low short-term revision rates did not perform as well with 
longer follow-up. However, although we observed variation in 
prosthesis-specific survival, the overall results were satisfac-
tory according to international standards.
BE performed the analyses and drafted the paper. All authors contributed to 
the study design, interpretation of results, and approved the final version.
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